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Salvia divinorum, whose main active ingredient is the neoclero-
dane diterpene Salvinorin A, is a hallucinogenic plant in the mint
family that has been used in traditional spiritual practices for its
psychoactive properties by the Mazatecs of Oaxaca, Mexico. More
recently, S. divinorum extracts and Salvinorin A have become more
widely used in the U.S. as legal hallucinogens. We discovered that
Salvinorin A potently and selectively inhibited 3H-bremazocine
binding to cloned  opioid receptors. Salvinorin A had no signifi-
cant activity against a battery of 50 receptors, transporters, and ion
channels and showed a distinctive profile compared with the
prototypic hallucinogen lysergic acid diethylamide. Functional
studies demonstrated that Salvinorin A is a potent  opioid agonist
at cloned  opioid receptors expressed in human embryonic
kidney-293 cells and at native  opioid receptors expressed in
guinea pig brain. Importantly, Salvinorin A had no actions at the
5-HT2A serotonin receptor, the principal molecular target respon-
sible for the actions of classical hallucinogens. Salvinorin A thus
represents, to our knowledge, the first naturally occurring nonni-
trogenous opioid-receptor subtype-selective agonist. Because
Salvinorin A is a psychotomimetic selective for  opioid receptors,
 opioid-selective antagonists may represent novel psychothera-
peutic compounds for diseases manifested by perceptual distor-
tions (e.g., schizophrenia, dementia, and bipolar disorders). Addi-
tionally, these results suggest that  opioid receptors play a
prominent role in the modulation of human perception.
Salvia divinorum, a member of the mint family, is a psycho-active plant that has been used in traditional spiritual
practices by the Mazatec people of Oaxaca, Mexico for many
centuries (1). S. divinorum also grows in California and has been
used as a legal hallucinogen for several years (2). Traditionally,
S. divinorum is ingested as a quid or smoked for its psychoactive
properties (1) and has been reported to have potent hallucina-
tory actions (1, 3). The main active ingredient of S. divinorum is
Salvinorin A (Fig. 1), a novel neoclerodane diterpene of known
absolute configuration (4) whose structure was determined by
single-crystal x-ray analysis in two independent studies (5, 6).
Salvinorin A is structurally distinct from the naturally occurring
hallucinogens N,N-dimethyltryptamine, psilocybin, and mesca-
line and synthetic hallucinogens such as lysergic acid diethylam-
ide (LSD), 4-bromo-2,5-dimethoxyphenylisopropylamine
(DOB), and ketamine. Salvinorin A has been reported to be the
most potent naturally occurring hallucinogen, with an effective
dose in humans in the 200- to 1,000-g range when smoked (1,
3). Salvinorin A thus rivals the synthetic hallucinogens LSD and
DOB in potency. Salvinorin A has been reported to induce an
intense hallucinatory experience in humans, with a typical
duration of action being several minutes to an hour or so (1).
Several prior investigations attempted unsuccessfully to iden-
tify the molecular and cellular targets responsible for the actions
of Salvinorin A (1, 3) by using mainly nonhuman molecular
targets. Since then, it has become widely recognized that the
pharmacological properties of rodent and human molecular
targets are frequently distinct (7), and that tissue-based radio-
ligand binding assays frequently yield inaccurate estimates of
drug potency and selectivity. Accordingly, we reexamined the
molecular pharmacological profile of the novel diterpene Salvi-
norin A at a large number of cloned human G protein-coupled
receptors (GPCRs), channels, and transporters. We report here
that Salvinorin A is a potent and selective  opioid receptor
(KOR) agonist and represents, to our knowledge, the first
nonalkaloid opioid subtype-selective drug. We suggest that
because the KOR has long been recognized as a target for
psychotomimetic agents, KOR antagonists may represent a
novel class of psychotherapeutic compounds. Our results also
suggest that the KORdynorphin peptide system functions to
modulate human perception.
Materials and Methods
Materials. Two sources of Salvinorin A were used for the studies
described here: Biosearch and the Salvia divinorum Research
and Information Center, Malibu, CA; both samples were iden-
tical by thin-layer chromatography and mass spectroscopy and
showed the expected molecular ion in the mass spectrum. In
addition, the Biosearch sample showed the reported melting
point (6), and the Varian 300 MHz NMR spectrum was identical
with that reported. The coding region of the KOR was cloned via
PCR-amplification of ‘‘Quick-Clone’’ cDNA (CLONTECH)
and subcloned into the eukaryotic expression vector pIRESNEO
via NotI adaptors to yield pIRESNEO-KOR. The entire insert
was verified by automated double-stranded DNA sequencing
(Cleveland Genomics, Cleveland). A stable human embryonic
kidney-293 cell line expressing the KOR was also constructed
(KOR-293) and was used for radioligand-binding and functional
assays. GF-62 cells, a stable cell line expressing the 5-HT2A
receptor (8), was used for functional studies of 5-HT2A receptors.
All other receptors were obtained as previously described (9, 10)
as part of the National Institute of Mental Health Psychoactive
Drug Screening Program (NIMH-PDSP) resource.
Frozen guinea pig brains and rat brains were purchased from
Harlan Bioproducts for Science (Indianapolis). [D-Ala-2-
MePhe4,Gly-ol5]enkephalin (DAMGO), D-Phe-Cys-Tyr-D-Trp-
Arg-Thr-Pen-Thr-NH2 (CTAP), and H-Tyr-Tic-Phe-Phe-OH
(TIPP) were obtained from Multiple Peptide Systems (San
Diego) through arrangement with Paul Hillery of the Research
Technology Branch, National Institute on Drug Abuse. SNC-80
was obtained from K.C.R. ()-Nor-binaltorphine 2HCl (Nor-
BNI) and ()-U69593 were obtained from Research Biochemi-
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cals (Natick, MA). [35S]Guanosine 5-(-thio)-triphosphate
([35S]-GTP[S], 45 TBqmmol) was purchased from DuPont
NEN. BSA, naloxone, GDP, and GTP[S] were purchased from
Sigma.
Radioligand-Binding Assays. Radioligand-binding assays at human
cloned GPCRs, ion channels, and transporters were performed
as previously detailed (9, 10) by using the resources of the
NIMH-PDSP. Detailed on-line protocols are available for all
assays at the NIMH-PDSP web site (http:pdsp.cwru.edu). 
opioid radioligand-binding assays in situ in guinea pig brain and
 opioid receptor (MOR)- and  opioid receptor (DOR)-binding
assays in rat brain were performed as previously detailed (11).
Initial screening assays were performed by using 10 M Salvi-
norin A or 10 M LSD by using quadruplicate determinations
and the percent inhibition of specific binding determined. Where
10 M test compound inhibited 50% of specific binding, Ki
determinations were performed by using six concentrations of
unlabeled ligand spanning a 10,000-fold dose range. Kis were
calculated by using GRAPHPAD PRIZM and represent the mean 
SEM of quadruplicate determinations.
Functional Assays. Phosphoinositide hydrolysis assays at 5-HT2A
receptors were performed as previously described (8, 12). 
opioid agonist-dependent inhibition of adenylate cyclase was
performed by using the KOR-cell line. Briefly, cells were split
into polylysine-coated 24-well plates and then incubated over-
night in serum-free medium. The next day, medium was replaced
with Hanks’ F12 medium containing 100 M isobutylmethyl-
xanthine and 100 M forskolin together with various concen-
trations of test agent. After incubation at 37°C for 15 min, the
reaction was terminated and cAMP content determined as
Fig. 1. Molecular modeling predicts Salvinorin A is a structurally novel  opioid ligand. A shows the structure of Salvinorin A, enadoline, U69593 and LSD
whereas B shows a superimposition of the structures of Salvinorin A and U69593. C shows potential residues on the KOR identified by molecular modeling, which
might interact with Salvinorin A, and D shows a model of Salvinorin A’s interactions with the KOR (see supporting information for further details).









described previously (13). All data reported here represent the
results of at least four separate experiments with EC50 and Emax
values calculated by using GRAPHPAD PRIZM (Graph PAD,
San Diego).
The 35S-GTP[S]-binding assay proceeded with modifications
of the methods described previously (14, 15). Guinea pig caudate
membranes, prepared as described previously (16) (10–20 g of
protein in 300 l of 50 mM TrisHCl, pH 7.4, with 1.67 mM DTT
and 0.15% BSA) were added to polystyrene 96-well plates filled
with 200 l of a reaction buffer containing 50 mM TrisHCl, pH
7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 100 M GDP,
0.1% BSA, 0.05–0.01 nM 35S-GTP[S], and varying concentra-
tions of drugs. The reaction mixture was incubated for 3 h at 22°C
(equilibrium). The reaction was terminated by the addition of 0.5
ml of ice-cold TrisHCl, pH 7.4 (4°C) followed by rapid vacuum
filtration through Whatman GFB filters previously soaked in
ice-cold TrisHCl, pH 7.4 (4°C). The filters were washed twice
with 0.5 ml of ice-cold distilled H2O (4°C). Bound radioactivity
was counted at an efficiency of 98% by liquid scintillation
spectroscopy. Nonspecific binding was determined in the pres-
ence of 10 M GTP[S].
Molecular Modeling. Molecular modeling investigations were con-
ducted by using the SYBL molecular modeling package (Ver. 6.7,
2001, Tripos Associates, St. Louis). Molecular mechanics min-
imizations of receptor models and complexes were performed
after the addition of hydrogen atoms by using the Tripos force
field with Gasteiger–Hückel charges (distance-dependent di-
electric constant, nonbonded cutoff  8 Å) without constraints
and were terminated at an energy gradient of 0.05 kcalmolÅ,
essentially as previously described (17–19) The UNITY program
within SYBL was used to perform the three-dimensional database
searches. Full details of the modeling methods and results are
published as supporting information (Tables 3–5) on the PNAS
web site, www.pnas.org.
Results
Salvinorin A Selectively Inhibits KOR Binding. To identify Salvinorin
A’s molecular target, we screened Salvinorin A (10 M) at a
large panel of mainly cloned human GPCRs, transporters, and
ligand-gated ion channels by using the resources of the NIMH-
PDSP. For comparison, we screened the same molecular targets
with the prototypic hallucinogen LSD, also at 10 M. As shown
in Fig. 1 and in supporting information, Salvinorin A inhibited
only [3H]-bremazocine-labeled KORs and did not significantly
inhibit binding to cloned human  (MOR) or  opioid (DOR)
receptors or any of the 48 other molecular targets screened. Ki
determinations (Table 1) showed that Salvinorin A was a potent
agonist of KOR and guinea pig (gp)KOR. Additionally, Salvi-
norin A had Ki values 5,000 nM at the gpMORs and gpDORs
(Table 1). These results indicate that Salvinorin A is, to our
knowledge, the first naturally occurring  opioid selective ligand.
By comparison, LSD potently inhibits the binding of a large
number of biogenic amine receptors (Fig. 1) with Kis 50 nM for
several GPCRs (data not shown). Interestingly, Salvinorin A had
no detectable affinity for the 5-HT2A serotonin receptor and did
not activate 5-HT2A receptors (not shown), which represent the
main molecular target responsible for the classical hallucinogens
such as LSD, N,N-dimethyltryptamine, psilocybin, mescaline,
and 4-bromo-2,5-dimethoxyphenylisopropylamine (20, 21).
Salvinorin A Represents a Structurally Novel KOR Ligand. Because
Salvinorin A represents a structurally novel hallucinogen, we
next performed molecular modeling studies to provide insights
into how this compound might interact with KORs. A previously
reported model of the KOR complexed with the KOR-selective
agonist U69593 was used as a starting point (22). This model has
the advantage that it was derived from a set of distance con-
straints between potential hydrogen bond-forming pairs unique
to the opioid receptor sequences themselves. The result thus
does not depend directly on any direct experimental structural
data for rhodopsins. Although this model was constructed before
the publication of the crystal structure of rhodopsin (23), it is
remarkable that the overall configurations are quite similar (rms
deviation  4  by fitting the helix C- atoms of identical
residues in both sequences). The U69593 KOR complex places
the arylacetamide portion of the ligand in a position analogous
to the tyramine moiety with the carbonyl hydrogen bonded to
Y139 (22). The only structural similarity between U69593 and
Salvinorin A (Fig. 2A) is the presence of an aromatic ring and the
amide and ester carbonyl groups separated by a short linkage.
Because of this similarity, and the nearly complete lack of
similarity of salvinorin and any known KOR ligand, the salvi-
norin crystal structure (5) was initially docked by superimposi-
tion of aromatic centroids and the carbonyl atoms of salvinorin
with those of bound U69593. The role of the carbonyl function-
ality for arylacetamide ligands as a hydrogen bond acceptor has
been demonstrated experimentally (24) and indirectly supports
the proposed role of Y139 and its interaction with the lactone
carbonyl of salvinorin. Multiple sterically allowed complexes
were generated by using a systematic conformational search
about all rotatable Y139 bonds, a dummy bond between a Y139
OH hydrogen atom, and salvinorin carbonyl, following a previ-
ously described method (18). Candidate complexes were evalu-
ated interactively for steric fit and hydrogen bond donating
properties of the receptor cavity visualized as a Connolly channel
plot color coded for hydrogen-bonding potential.
Only one family of complexes allowed simultaneous hydrogen
bond formation between the receptor side chains and ligand
features shown in Fig. 2C (see Table 3 for additional modeling
results and details of modeling procedures). In this orientation,
the furan substituent of Salvinorin A pointed toward TM1 and
TM2, the 4-methoxycarbonyl toward TM5 and TM6, with the A
and C rings toward the extra- and intracellular sides, respectively
(Fig. 2D and supporting information). Not unexpectedly, there
is very little atom-by-atom correspondence between bound
U69593 and Salvinorin A, although both occupy a similar space
(Fig. 2B). Docking of salvinorin into hydrogen bond potential-
coded Connolly channels defining the binding sites of the MOR
and DOR models (22) indicates that salvinorin is sterically
compatible with each in slightly different binding modes but
could not as readily accommodate the four-point hydrogen bond
donoracceptor scheme (Fig. 2D) seen with the KOR receptor
(e.g., the KOR models could accommodate the furan oxygen and
4-methoxycarbonyl functionality but not the 2-acetoxy group).
Residues potentially forming the salvinorin-binding site of the
KOR receptor model are listed in Table 4. The identities of 11
of these are conserved in both the MOR and DOR, whereas the
remaining seven are variable. The variable residues cause sig-
nificant alterations in the steric and electronic characteristics of
MOR and DOR in the regions analogous to the salvinorin-
binding site of the KOR. The substantial differences in the
region of the salvinorin-binding site between the KOR and
MORDOR receptors are consistent with the observed KOR
selectivity of salvinorin.
Table 1. Salvinorin A is a potent and selective  opioid ligand
 Ki  Ki  Ki (pKi  SEM)
Cloned receptors 10,000 nM 10,000 nM 16 (7.2  0.06)
Brain receptors 5,000 nM 5,000 nM 4.3 (8.6  0.05)
Shown are mean Ki values for Salvinorin A at cloned receptors expressed in
human embryonic kidney-293 cells or opioid receptors expressed in situ in rat
(, ) or guinea pig brain (). Data represent mean  SEM of computer-derived
estimates of Ki and pKi values for n  3 separate experiments.
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The proposed KOR salvinorin-binding site model is also
consistent with what little is known about the structural features
of salvinorin required for psychotropic activity. For example, the
one-position carbonyl of salvinorin is not able to form specific
donoracceptor contacts with residues in the receptor model,
partially because of its sterically hindered environment, and is
Fig. 2. Large-scale screening of human cloned GPCRs reveals Salvinorin A is selective for KOR. Shown is the mean percent inhibition of radioligand binding
or functional activity (metabotropic glutamate receptors only) to 50 receptors and transporters for LSD (yellow bars) and Salvinorin A (red bars) tested at 10 M.
With the exception of the rat 1 and 2 adrenergic and bovine dopamine transporter (DAT) all of the assays were performed with cloned human receptors
heterologously expressed (see Materials and Methods and supporting information on the PNAS web site for details). As can be seen (arrow), Salvinorin A inhibited
only KOR binding at 10 M. See Table 5 for details. SERT, serotonin transporter; NET, norepinephrine transporter; DAT, dopamine transporter; rGABAA, rat
GABA-A receptor.









not essential for psychotropic activity (25). The 2-acetoxy group
of salvinorin does make specific donoracceptor contacts in the
model and is required for activity (5). Interestingly, a three-
dimensional search of the National Cancer Society Database
using the pharmacophore features and geometries derived from
salvinorin docked with the KOR model produced splendidin (26)
and deoxydeoxygedunin (27) (not shown). Splendidin was orig-
inally isolated from Salvia splendens, a species distinct from S.
divinorum and from which salvinorin is derived. S. splendens has
been reported to have psychotropic activity.
Salvinorin A Is a Potent KOR Agonist at Recombinant KORs and KORs
Expressed in Situ. We next examined the agonistantagonist
properties of Salvinorin A by using two model systems: KOR
stably expressed in human embryonic kidney-293 cells and
gpKOR expressed in situ in guinea pig brain. As shown in Fig.
3, Salvinorin A was a potent KOR agonist with an EC50 for
inhibition of adenylate cyclase of 1.05 nM as compared with an
EC50 for the KOR agonist U69593 of 1.2 nM (Table 2).
Salvinorin A was also a potent agonist at gpKOR expressed in
situ with an EC50 for [35S]GTP[S] binding of 235 nM with
U69593 having an EC50 of 377 nM (Table 2). Taken together,
these results indicate that Salvinorin A represents, to our
knowledge, the first nonnitrogenous KOR-selective agonist.
Discussion
The main finding of this paper is that Salvinorin A, the active
ingredient of the hallucinogenic plant S. divinorum, is a potent
and selective KOR agonist. Salvinorin A is a novel nonalkaloid
diterpene that has no structural resemblance to any known
hallucinogens but does have modest structural homology to
enadoline, a selective KOR agonist (Fig. 1 A and C). Salvinorin
A thus represents a class of hallucinogens with potent actions at
KORs. Because KOR agonists have long been known to have
psychotomimetic actions (28), these results imply that the actions
of Salvinorin A in humans are mediated, at least in part, via
activation of KORs. Additionally, these results imply that KOR-
selective antagonists could conceivably represent treatments for
diseases in which hallucinations are prominent, including schizo-
phrenia, depression with psychotic features, and the hallucinosis
associated with certain dementias (Alzheimer’s, Huntington’s,
and Pick diseases) and certain types of drug abuse (e.g., am-
phetamine and cocaine psychosis) (29, 30). Previous studies
evaluating naltrexone, which is a nonselective opioid antagonist,
for the treatment of schizophrenia have yielded equivocal results
(31, 32).
Dynorphin was discovered in 1979 by Goldstein et al. (33) and
was demonstrated to be an extraordinarily potent endogenous
peptide with selectivity for the KOR (34), a GPCR in the opioid
receptor family (35). Before the cloning of the KOR, a large
amount of behavioral (36, 37), developmental (38, 39), and
biochemical (40, 41) data suggested the existence of distinct
KORs. Although dynorphin and related peptides represent, in
some cases, potent and relatively selective endogenous ligands
for the KOR, other types of naturally occurring ligands have
heretofore not been identified. The discovery that Salvinorin A
is a potent naturally occurring nonalkaloid agonist for the KOR
is thus unexpected.
Fig. 3. Salvinorin A is a potent KOR agonist. A shows that Salvinorin A
potently inhibits 3H-bremazocine binding to cloned KORs, whereas B shows
the ability of Salvinorin A to inhibit forskolin-stimulated adenylate cyclase in
KOR-393 cells. Data represent the mean  SD of triplicate determinations
from a representative experiment that has been replicated three times. For
the inhibition of forskolin-stimulated cyclase activity, an EC50 value of 1  0.5
nM was calculated for Salvinorin A, compared with an EC50 value of 1.2  0.6
nM for U69593.
Table 2. Salvinorin A is a potent -opioid agonist: [35S]GTP--S studies using guinea pig brain
caudate membranes
Drug Unblocked CTAP, 200 nM TIPP, 20 nM Nor-BNI, 0.2 nM
Percent stimulation
DAMGO 414  47 11,124  2,126 494  56 355  61
0.96  0.02 0.99  0.09 0.97  0.02 0.92  0.03
SNC80 758  131 987  120 9,565  4,115 855  119
0.91  0.04 0.94  0.03 0.90  0.19 0.86  0.3
U69,593 377  39 540  57 442  76 1,554  168
1.70  0.04 1.70  0.04 1.60  0.06 1.60  0.05
Percent of maximal stimulation produced by 10 M U69,593
Salvinorin A 235  26 204  20 259  40 643  128
0.79  0.04 0.83  0.03 0.81  0.06 0.89  0.10
[35S]-GTP--S-binding assays were conducted as described in Materials and Methods. Agonist dose–response
curves were generated by using 8–10 drug concentrations in the absence and presence of fixed concentrations
of selective antagonists: CTAP to block  receptors, TIPP to block  receptors, and nor-BNI to block  receptors. The
concentrations were chosen on the basis of previous studies to selectively block the targeted receptor. Values in
parentheses are the maximal percent stimulation. For Salvinorin-A, the value is reported as a percent of the
stimulation produced by 10 M U69,593. Each value is  SD (n  3). DAMGO, [D-Ala-2-MePhe4,Gly-ol5]enkephalin;
CTAP, D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2; TIPP, H-Tyr-Tic-Phe-Phe-OH.
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It is now well established that the activation of KORs induces
a large number of behavioral effects that include analgesia,
sedation, and perceptual distortions. In the past, studies on the
precise role of KORs in humans were hampered by the lack of
selective agonists, although studies with compounds such as
cyclazocine and ketocyclazocine suggested that KOR agonists
were psychotomimetic (28). More recently, human studies with
the highly selective KOR agonist enadoline (42) indicated that
KOR activation induced visual distortions, feelings of unreality,
and depersonalization. These effects of enadoline are reminis-
cent of those previously reported for Salvinorin A (2, 3). Taken
together, these results suggest that the KORdynorphinergic
system functions to modulate human perception and cognition,
as might be inferred from detailed anatomical studies of dynor-
phin peptide distribution studies (43–45).
One of the implications of these results is that KORs or KOR
signaling may also be important in the pathogenesis of diseases
characterized by perceptual distortions. The most obvious dis-
eases implicated are schizophrenia, dementia, and bipolar dis-
orders, because all are characterized by hallucinations and
delusions. Prior studies evaluating KORs in schizophrenia have
yielded conflicting results (46–48), whereas one study examining
affective disorder was negative (47). On the other hand, two
well-controlled studies have demonstrated an up-regulation of
KORs in Alzheimer’s disease (49, 50), whereas MORs and
DORs were down-regulated (50) or unchanged (49).
In conclusion, we report the discovery that Salvinorin A is a
potent selective KOR agonist. Salvinorin A thus represents a
unique structural class of nonnitrogenous opioid subtype-
selective agonists. Additionally, these results suggest that KORs
play a prominent role in the regulation of human perception and
suggest that KOR antagonists could represent a novel drug class
with specific activity in diseases in which alterations in percep-
tion are predominant. Finally, these results imply that the
KORdynorphinergic system functions to modulate human per-
ception and cognition.
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